BMO Capital downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

Spark Therapeutics (ONCE) PT Lowered to $77 at BarclaysAugust 8, 2018 5:11 AM Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson HumphreyAugust 7, 2018 3:32 PM Spark Therapeutics (ONCE) PT Lowered to $80 at CowenAugust 7, 2018 3:31 PM Spark Therapeutics (ONCE) PT Lowered to $64 at RBC CapitalAugust 7, 2018 2:31 PM UPDATE: Credit Suisse Double Downgrades Spark Therapeutics (ONCE) to UnderperformAugust 7, 2018 2:26 PM UPDATE: Citi Upgrades Spark Therapeutics (ONCE) to Buy, Sees M&A Value Upwards of $130/ShareAugust 7, 2018 11:55 AM Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect PerfectionAugust 7, 2018 9:34 AM Spark Therapeutics (ONCE) Reports Q2 Loss Per Share of $2.07August 7, 2018 7:35 AM